OverviewSuggest Edit

Acceleron Pharma is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of treatments for hematologic, neuromuscular, and pulmonary diseases. The company specializes in TGF-beta biology and protein engineering to regulate cellular growth and repair.

TypePublic
Founded2003
HQCambridge, MA, US
Websiteacceleronpharma.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Dec 2019)237(+37%)
Job Openings36
Revenue (FY, 2020)$92.5 M(+26%)
Share Price (Oct 2021)$172.9
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

CFO
Jay T. Backstrom

Jay T. Backstrom

EVP, Head of Research and Development
James Desiderio

James Desiderio

SVP, Regulatory and Quality
Todd James

Todd James

SVP, Corporate Affairs and Investor Relations
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
Show more

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, MA, US (HQ)
128 Sidney St
Show all (1)

Acceleron Pharma Financials and Metrics

Acceleron Pharma Revenue

Acceleron Pharma's revenue was reported to be $92.52 m in FY, 2020
USD

Revenue (Q1, 2021)

24.8m

Net income (Q1, 2021)

(63.5m)

EBIT (Q1, 2021)

(63.6m)

Market capitalization (15-Oct-2021)

10.6b

Closing stock price (15-Oct-2021)

172.9

Cash (31-Mar-2021)

455.5m

EV

10.1b
Acceleron Pharma's current market capitalization is $10.6 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

13.5m14.0m74.0m92.5m

Revenue growth, %

(51%)4%429%

General and administrative expense

33.7m34.5m56.5m85.9m

R&D expense

89.7m103.9m154.0m173.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

3.7m3.1m3.0m3.2m3.7m3.3m2.8m27.7m4.2m4.3m25.0m24.8m

General and administrative expense

7.8m11.4m7.5m7.4m7.7m8.7m10.8m14.0m15.5m18.3m31.1m

R&D expense

21.7m21.6m21.1m23.4m25.9m24.7m32.8m34.8m37.6m37.7m57.3m

Operating expense total

29.6m33.0m28.6m30.9m33.6m33.3m43.6m48.8m53.1m55.9m88.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

100.2m144.1m237.7m671.0m

Accounts Receivable

3.6m7.0m8.5m

Prepaid Expenses

4.4m7.7m10.0m17.3m

Current Assets

285.2m306.0m449.9m893.3m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(108.5m)(118.9m)(124.9m)(166.0m)

Depreciation and Amortization

2.8m3.7m3.9m

Accounts Payable

(504.0k)(673.0k)1.9m5.8m

Cash From Operating Activities

(76.7m)(94.7m)(93.8m)(130.3m)
USDQ1, 2017

Financial Leverage

1.1 x
Show all financial metrics

Acceleron Pharma Operating Metrics

FY, 2017FY, 2018FY, 2019

Patent Applications

492505637

Patents Issued

635708788
Show all operating metrics

Acceleron Pharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Acceleron Holding Ltd.
Acceleron Securities Corp.

Acceleron Pharma Revenue Breakdown

Embed Graph

Acceleron Pharma revenue breakdown by business segment: 81.1% from License and Milestone and 18.9% from Cost-Sharing

Acceleron Pharma Online and Social Media Presence

Embed Graph

Acceleron Pharma Company Culture

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Acceleron Pharma News and Updates

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Acceleron Pharma Inc. Buyout

WILMINGTON, Del., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Acceleron Pharma Inc. (“Acceleron”) (NASDAQ GM: XLRN) regarding possible breaches of fiduciary duties and other violations of law related to Acceleron’s agreement to be acquired by Merck &am…

Thinking about trading options or stock in Pfizer, Callon Petroleum, Acceleron Pharma, Tesla, or Expedia Group?

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, CPE, XLRN, TSLA, and EXPE. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Acceleron Pharma stock jumps after positive heart-drug study

Acceleron Pharma Inc. shares gained in after-hours trading Wednesday after the pharmaceutical company revealed positive results from a study of a drug for heart disease. The company announced that a phase 2 study of a drug called sotatercept helped patients with pulmonary arterial hypertension show…

Acceleron Pharma stock soars more than 50% on hypertension drug study

Acceleron Pharma Inc. shares surged in the extended session late Monday after the biotech drug maker said its hypertension drug hit key goals in a mid-stage clinical trial. Acceleron shares soared 56% after hours, following a 1.6% rise to close Monday at $52.87. At Monday's close, the company had a…

Acceleron Pharma stock down 4% after company halts treatment trial

Shares of Acceleron Pharma Inc. fell nearly 4% in the extended session Monday after the biopharmaceutical company said one of its treatments aimed at a type of muscular dystrophy showed no evidence of benefits relative to a placebo. The company has stopped further clinical trials, saying it was "di…

Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia

U.S. Food and Drug Administration sets target action date of April 4, 2020 for myelodysplastic syndromes indication.read more
Show more

Acceleron Pharma Blogs

Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis

Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis Content Import Tue, 12/01/2020 - 07:00 Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis Dec 01, 2020 This rel…

Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions

Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions Content Import Fri, 11/13/2020 - 10:01 Acceleron Presents Preliminary Interim Data from the SPECTRA …

Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions

Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions Content Import Fri, 11/13/2020 - 10:00 Acceleron Presents New Data from the PULSAR Phase …

Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions

Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions Content Import Mon, 11/09/2020 - 07:01 Acceleron Announces Clinical Trial Updates, Preclinical Presentatio…

Acceleron Reports Third Quarter 2020 Operating and Financial Results

- Acceleron recognized approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL ® (luspatercept-aamt) - - REBLOZYL, the first and only erythroid maturation agent, was approved by Health Canada for the treatment of transfusion-dependent

Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales

- Acceleron expects to report approximately $19.3 million in royalty revenue for Q3 2020 from approximately $96 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb - - Acceleron will report its full third quarter 2020 financial and operating results after the
Show more

Acceleron Pharma Frequently Asked Questions

  • When was Acceleron Pharma founded?

    Acceleron Pharma was founded in 2003.

  • Who are Acceleron Pharma key executives?

    Acceleron Pharma's key executives are Habib Dable, Kevin McLaughlin and Jay T. Backstrom.

  • How many employees does Acceleron Pharma have?

    Acceleron Pharma has 237 employees.

  • What is Acceleron Pharma revenue?

    Latest Acceleron Pharma annual revenue is $92.5 m.

  • What is Acceleron Pharma revenue per employee?

    Latest Acceleron Pharma revenue per employee is $390.4 k.

  • Who are Acceleron Pharma competitors?

    Competitors of Acceleron Pharma include Portola Pharmaceuticals, GBT (Global Blood Therapeutics) and Theravance Biopharma.

  • Where is Acceleron Pharma headquarters?

    Acceleron Pharma headquarters is located at 128 Sidney St, Cambridge.

  • Where are Acceleron Pharma offices?

    Acceleron Pharma has an office in Cambridge.

  • How many offices does Acceleron Pharma have?

    Acceleron Pharma has 1 office.